Skip to content

US · NVS · DRUG MANUFACTURERS - GENERAL

Novartis AG (NVS) intrinsic value and stock valuation

$150.47as of 2026-11-21 · Mkt cap 293.55B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Novartis AG DCF and intrinsic value

InvestorsCraft values NVS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NVS’s statements →

Novartis AG Graham Number

Graham Number: $62.58d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Basel, BS 4056 novartis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$54.8B+1.9% 5y CAGRd
20112025
Net income
$14.1B+11.7% 5y CAGRd
20112025
Free cash flow
$17.7B+9.8% 5y CAGRd
20112025
Total equity
$46.5B-3.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$54.8B$51.7B$46.7B$43.5B$44B
Operating income$17.1B$14.5B$9.77B$7.95B$10.1B
Net income$14.1B$11.9B$14.9B$6.96B$24B
EPSd$7.19M$5.87M$7.1M$3.17M$10.6M
Operating cash flow$19.2B$17.6B$14.5B$14.2B$15.1B
Capital expenditure-$-1.56B-$-3.81B-$-2.75B-$-2.24B-$-2.56B
Free cash flow$17.7B$13.8B$11.7B$12B$12.5B
Total assets$115.6B$102.2B$99.9B$117.5B$131.8B
Total debt$37B$31.3B$26.3B$27.9B$31B
Net debt$25.6B$19.8B$13B$20.4B$18.6B
Total equity$46.5B$44.1B$46.8B$59.4B$67.8B
Cash and short-term investments$11.6B$13.4B$14B$18.6B$28.1B
Income statement
20252024202320222021
Revenue$54.8B$51.7B$46.7B$43.5B$44B
Cost of revenue$13.7B$12.8B$12.5B$11.6B$11.7B
Gross profit$41.1B$38.9B$34.2B$31.9B$32.2B
Research and development expenses$10.7B$10B$11.4B$9.17B$8.64B
Selling, general and administrative expenses$13.3B$12.6B$12.5B$12.2B$12.8B
Other expenses$0.00$1.76B$531M$2.57B$715M
Operating expenses$24B$24.4B$24.4B$23.9B$22.2B
Cost and expenses$37.7B$37.2B$36.9B$35.5B$33.9B
Interest income$374.9M$567.7M$629.2M$377.7M$71M
Interest expense$1.19B$1.04B$876.1M$834.6M$905M
Depreciation and amortization$5.35B$6.07B$8.28B$6.71B$5.6B
Ebitda$23B$20.7B$18.3B$14.7B$30.9B
Operating income$17.1B$14.5B$9.77B$7.95B$10.1B
Total other income/expenses, net-$-638.25M-$-904M-$-646M-$-769M$14.5B
Income before tax$16.4B$13.6B$9.12B$7.18B$24.5B
Income tax expense$2.4B$1.7B$551M$1.13B$1.63B
Net income$14.1B$11.9B$14.9B$6.96B$24B
Weighted average shares outstanding$1.94B$2.02B$2.08B$2.18B$2.24B
Weighted average diluted shares outstanding$1.96B$2.04B$2.09B$2.2B$2.26B
Balance sheet
20252024202320222021
Cash and short-term investments$11.6B$13.4B$14B$18.6B$28.1B
Net receivables$10.9B$8.21B$9.38B$9.89B$9.62B
Inventory$6.27B$5.72B$5.91B$7.18B$6.67B
Total current assets$30.5B$29.7B$30.5B$36.9B$45.7B
Property, plant and equipment, net$12.4B$10.9B$10.9B$12.2B$13.1B
Goodwill and intangible assets$55B$51.7B$50.2B$60.9B$63.8B
Long-term investments$2.3B$1.13B$1.83B$1.61B$2.27B
Total non-current assets$85.1B$72.5B$69.5B$80.5B$86.1B
Total assets$115.6B$102.2B$99.9B$117.5B$131.8B
Accounts payable$4.46B$4.57B$4.93B$5.15B$5.55B
Short-term debt$5.78B$8.32B$6.31B$6.13B$6.5B
Deferred revenue$0.00$127M$98M$123M$123M
Total current liabilities$27.3B$28.7B$26.4B$28.7B$30.2B
Long-term debt$31.2B$22.9B$20B$21.8B$24.5B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$41.7B$29.4B$26.8B$29.4B$33.8B
Capital lease obligations$1.66B$1.8B$1.83B$1.79B$1.9B
Total liabilities$69B$58.1B$53.2B$58B$64B
Common stock$766M$793M$825M$890M$901M
Retained earnings$44.7B$46.6B$49.6B$63.5B$71B
Accumulated other comprehensive income (loss)$694M-$-3.26B-$-3.77B-$-5B-$-4.19B
Total equity$46.5B$44.1B$46.8B$59.4B$67.8B
Total investments$2.46B$3.02B$2.4B$12.7B$18B
Total debt$37B$31.3B$26.3B$27.9B$31B
Net debt$25.6B$19.8B$13B$20.4B$18.6B
Cash flow statement
20252024202320222021
Net income$14.1B$11.9B$8.57B$6.05B$22.9B
Depreciation and amortization$5.35B$6.07B$8.28B$6.71B$5.6B
Stock-based compensation$0.00$1.04B$865M$791M$700M
Change in working capital-$-3.08B-$-706M-$-369M-$-796M-$-73M
Accounts receivable-$-1.13B-$-931M-$-1.5B-$-397M-$-352M
Inventory$34.2M-$-225M-$-546M-$-560M-$-102M
Accounts payable-$-274.4M-$-105M$479M-$-181M-$-111M
Net cash provided by operating activities$19.2B$17.6B$14.5B$14.2B$15.1B
Investments in property, plant and equipment-$-3.92B-$-1.37B-$-1.06B-$-916M-$-1.07B
Acquisitions, net-$-3.01B-$-3.83B-$-3.57B-$-864M$20.5B
Net cash used for investing activities-$-4.9B-$-7.51B$5.6B$1.47B$4.21B
Common stock issued$27.1M$0.00$0.00$0.00$0.00
Common stock repurchased-$-9.26B-$-8.33B-$-8.72B-$-10.65B-$-3.06B
Dividends paid-$-7.86B-$-7.62B-$-7.26B-$-7.51B-$-7.37B
Net cash used for financing activities-$-14.94B-$-11.74B-$-14.28B-$-20.56B-$-16.26B
Net change in cash-$-24M-$-1.93B$5.88B-$-4.89B$2.75B
Cash at end of period$11.4B$11.5B$13.4B$7.52B$12.4B
Operating cash flow$19.2B$17.6B$14.5B$14.2B$15.1B
Capital expenditure-$-1.56B-$-3.81B-$-2.75B-$-2.24B-$-2.56B
Free cash flow$17.7B$13.8B$11.7B$12B$12.5B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Novartis AG

        Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

        CEO
        Vas Narasimhan
        Employees
        75.27K
        Beta
        0.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Novartis AG (NVS)?

        Novartis AG (NVS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NVS undervalued?

        NVS trades at a price of $150.47 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.